Prenatal diethylstilbestrol exposure and self-reported immune-related diseases

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 77, Issue 2, 1998, Pages 205-209

  Vingerhoets, A J J M ^a   Assies, J ^b   Goodkin, K ^c   Van Heck, G L ^a   Bekker, M H ^a  

^a TILBURG UNIVERSITY   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Immunity; Prenatal diethylstilbestrol exposure; Self reported health status

Indexed keywords

DIETHYLSTILBESTROL;

ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; FEMALE; GENITAL MALFORMATION; HEALTH STATUS; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; PRENATAL EXPOSURE; PRIORITY JOURNAL; SELF REPORT; VAGINA ADENOSIS;

EID: 0032053720     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(97)00274-1     Document Type: Article

References (28)

1. [1] Emens JM. Continuing problems with diethylstilbestrol. Br J Obstet Gynaecol 1994;101:748-50.
2. [2] Giusti RM, Iwamoto K, Hatch EE. Diethylstilbestrol revisited: A review of the long-term health effects. Ann Intern Med 1995;122:778-88.
3. [3] Herbst AL. Problems of prenatal DES exposure. In: Herbst AL, Mishell DR, Stenchever MA, Drögemüller W, editors. Comprehensive gynecology. St. Louis, MI: Mosby Year Book, 1992:409-23.
4. [4] Kaufman RH, Binder GL, Gray PM, Adam E. Upper genital tract changes associated with exposure in utero to diethylstilbestrol. Am J Obstet Gynecol 1977;128:51-9.
5. [5] Mittendorf R. Teratogen update: Carcinogenesis and teratogenesis associated with exposure to diethylstilbestrol (DES) in utero. Teratology 1995;51:435-45.
6. [6] Marselos M, Tomatis L. Diethylstilbestrol I: Pharmacology, toxicology and carcinogenicity in humans. Eur J Cancer 1992;28A:1182-9.
7. [7] Verheijen RHM, Schijf CPT, Van Dongen PWJ, Van der Zanden PHT, Bakker EHM. Gynaecologische en obstetrische consequenties van blootstelling aan diethylstilbestrol (DES) in utero herbelicht. Ned T Gen 1991;135:89-93.
8. [8] Walker BE, Kurth L. Pituitary tumors in mice exposed prenatally to diethylstilbestrol. Cancer Res 1993;53:1546-9.
9. [9] Vessey MP, Fairweather DVI, Norman-Smith B, Buckley J. A randomized double-blind trial of the value of stilboestrol therapy in pregnancy: Long-term follow-up of mothers and their offspring. Br J Obstet Gynaecol 1983;90:1007-17.
10. [10] Schachter SC. Handedness in women with intrauterine exposure to diethylstilbestrol. Neuropsychologia 1994;32:25-34.
11. [11] Scheirs JGM, Vingerhoets AJJM. Handedness and other laterality indices in women prenatally exposed to DES. J Clin Exp Neuropsychol 1995;17:725-30.
12. [12] Assies J, Vonk J, Bleker O, Lumey L. Diethylstilbestrol (DES) related endocrine disturbances in women. Ann New York Acad Sci 1995;761:369-72.
13. [13] Assies J. Hyperprolactinaemia in diethylstilbestrol-exposed women. Letter to the editor. Lancet 1991;337:983.
14. [14] Wingard DL, Turiel J. Long-term effects of exposure to diethylstilbestrol. West J Med 1988;149:551-4.
15. [15] Blair BP. Immunological consequences of early exposure of experimental rodents to diethylstilbestrol and steroid hormones. In: Bern HA, Herbst AL, editors. Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme Stratton, 1981:167-78.
16. [16] Blair PB. Immunologic consequences of prenatal exposure to hormones. In: Giusti RM, editor. Report of the NIH workshop on long-term effects of exposure to diethylstilbestrol (DES). Washington, DC: US Department of Health and Human Services, Public Health Service, NIH, 1992:30-1.
17. [17] Kalland T, Holmdahl R. Estrogens and immunity: Long-term consequences of neonatal imprinting of the immune system by diethylstilbestrol. In: Mori T, Nagasawa H, editors. Toxicity of hormones in perinatal life. Boca Raton, F1: CRC Press, 1988:111-25.
18. [18] Ford CD, Johnson GH, Smith WG. Natural killer cells in utero diethylstilbestrol-exposed patients. Gynecol Oncol 1983;16:400-4.
19. [19] Ways SC, Mortola JF, Zvaifler NJ, Weiss RJ, Yen SS. Alterations in immune responsiveness in women exposed to diethylstilbestrol in utero. Fertil Steril 1987;48:193-7.
20. [20] Noller KL. Medical and surgical diseases in DES-exposed women. In: Giusti RM, editor. Report of the NIH workshop on long-term effects of exposure to diethylstilbestrol (DES). Washington DC: US Department of Health and Human Services, Public Health Service, NIH, 1992:34-5.
21. [21] Goodkin K, Antoni MH, Sevin B, Fox BH. A partially testable model of psychosocial factors in the etiology of cervical cancer. I. Biological, psychological and social aspects. Psycho-Oncology 1993;2:79-98.
22. [22] Mathur S, Mathur RS, Dowda H, Williamson HO, Faulk WP, Fudenberg HH. Sex steroid hormones and antibodies to Candida albicans. Clin Exp Immunol 1978;33:79-87.
23. [23] Andriole VT, Cohn GL. The effect of diethylstilbestrol on the susceptibility of rats to hematogenous pyelonephritis. J Clin Invest 1964;43:1136-45.
24. [24] Bekker MH, Van Heck GL, Vingerhoets AJJM. Gender identity, body experience, sexuality, and the wish for getting children in DBS-daughters. Women and Health 1996;24:65-82.
25. [25] Harrowe G, Mitsuhashi M, Payan DG. Measles virus - substance P receptor interactions. J Clin Invest 1990;85:1324-7.
26. [26] Noller KL, Blair PB, O'Brien PC, Melton LJ, Offord JR, Kaufman RH et al. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol. Fertil Steril 1988;49:1080-2.
27. [27] Goodkin K, Fletcher MA, Cohen N. Clinical aspects of psychoneuroimmunology. Lancet 1995;345:183-4.
28. [28] Goodkin K, Antoni MH, Sevin B, Fox BH. A partially testable model of psychosocial factors in the etiology of cervical cancer. II. Psychoneuroimmunological aspects, critique and prospective integration. Psycho-Oncology 1993;2:99-121.